MDM2 and neoplasm: In MCF-7 and HepG2 xenograft models, intraperitoneal administration of SP-141 at a 40 mg/kg dose for 5 days a week decreased MDM2 levels in tumors and inhibited tumor growth significantly after 42 and 20 days of treatment, respectively.